ABIOMED Schedules Earnings Release and Conference Call for Fiscal 2004 Second Quarter.

Business Editors/Health/Medical Writers

DANVERS, Mass.--(BUSINESS WIRE)--Oct. 23, 2003

ABIOMED, Inc., (NASDAQ:ABMD) today announced that it plans to report its financial and operating results for its fiscal second quarter ended September 30, 2003 on Thursday, October 30, 2003

The announcement will be followed by a discussion of the Company's financial results and other recent developments via a live web cast beginning at 11:00 a.m. Eastern Time. You may participate in the web cast through a link to be accessed on the Company's web site at www.abiomed.com.

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. The Company's AbioCor(R) Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. ABIOMED currently manufactures and sells the BVS(R) 5000 Biventricular Support System and the AB5000(TM) Circulatory Support System for the temporary support of all patients with failing but potentially recoverable hearts.